All News
Filter News
Found 39 articles
-
Attralus Appoints James Testa as Vice President of Finance
2/10/2022
Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced the appointment of James Testa as Vice President of Finance.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
Attralus Presents Positive New Data at 2021 American Society of Hematology Annual Meeting
12/13/2021
Attralus, Inc. today announced encouraging new preclinical data for AT-03, the company’s first-in-class pan-amyloid removal (PAR) therapeutic being developed for the treatment of systemic amyloidosis.
-
Attralus to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
11/22/2021
Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, is pleased to announce the company’s participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference.
-
Attralus to Present New Data at 2021 American Society of Hematology Annual Meeting
11/4/2021
Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced that new preclinical data for AT-03, the company’s first-in-class pan-amyloid removal therapeutic being developed for the treatment of systemic amyloidosis, will be presented at the 2021 American Society of Hematology Annual Meeting.
-
Money on the Move: September 8 – 14
9/15/2021
Ramping up after the Labor Day holiday, funds are flowing fast and free into these life science companies. -
Attralus Therapeutics has had a fresh set of faces shuffling into its executive suite in the past few months. And apparently with new leadership comes new funding opportunities.
-
Attralus Closes $116 Million Series B Financing
9/8/2021
Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced that it has closed a $116 million Series B financing.
-
BioSpace Movers & Shakers, July 30, 2021
7/30/2021
Biopharma and life science companies strengthen their leadership teams and boards with these Movers & Shakers. -
Attralus Appoints Jake Bauer to Board of DirectorsStrengthens Board with seasoned biopharmaceutical industry executive
7/28/2021
Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced that Jake Bauer joined the company’s Board of Directors as an independent director.
-
Clinical Catch-Up: June 14-18
6/21/2021
It was another busy week of clinical trial announcements. Here’s a look. -
Attralus Announces Presentation of Clinical Data on AT-01, a Novel Diagnostic for Systemic Amyloidosis, at the 2021 Society of Nuclear Molecular Imaging Meeting
6/15/2021
Attralus announced the presentation of clinical data for AT-01, a first-in-class pan-amyloid imaging agent, at the 2021 Society of Nuclear Molecular Imaging annual meeting by the company’s co-founder and interim Chief Scientific Officer, Jonathan Wall, PhD, a distinguished professor and director of the University of Tennessee Graduate School of Medicine’s Amyloidosis and Cancer Theranostics Program.
-
Attralus Announces Presentation of Clinical Data on AT-01, a Novel, Potential First-in-Class Diagnostic for Systemic Amyloidosis at the 2021 American College of Cardiology Annual Meeting
5/17/2021
Attralus announced presentation of clinical data at the 2021 American College of Cardiology annual meeting by the company’s co-founder and interim Chief Scientific Officer, Jonathan Wall, PhD, who is a distinguished professor and director of research at the University of Tennessee Graduate School of Medicine’s Amyloidosis and Cancer Theranostics Program.
-
Attralus Therapeutics Appoints Mark Timney as CEO and Expands Leadership Team with New Executives
5/10/2021
Attralus, backed by venBio Partners, recruits new leadership team to support advancement of its pipeline to bring transformational pan-amyloid removal therapies to the systemic amyloidosis field
-
Attralus Presents Clinical Data from Novel, Potential First-in-Class Diagnostic AT-01 for Systemic Amyloidosis at Virtual ASH 2020
12/6/2020
Data demonstrate potential to differentiate between the two major forms of amyloidosis - ATTR and AL - and non invasive detection of systemic AL amyloidosis in multiple organ systems
-
Attralus to Present Clinical Data at Upcoming Virtual ASH 2020
11/5/2020
Clinical update on the detection of Immunoglobulin Light Chain (AL) amyloidosis and differentiation between AL and Transthyretin (ATTR) amyloidosis using AT-01, a novel, potential first-in-class diagnostic for systemic amyloidosis
-
California-based biopharmaceutical company Attralus announced today that it has concluded a $25 million Series A financing round.
-
Attralus Launches with $25 Million Series A Financing from venBio Partners to Transform Treatment for Patients with Systemic Amyloidosis
9/14/2020
Leverages proprietary pan-amyloid targeting agents with potential to diagnose and reverse the underlying pathology of systemic amyloid diseases, including AL and ATTR amyloidosis [14-September-2020] SOUTH SAN FRANCISCO, Calif. , Sept. 14, 2020 /PRNewswire/ -- Attralus, a biopharmaceutical company focused on creating transformative medicines to improve the lives of pat
-
Attralus Presents Preclinical and Clinical Data at 17th International Symposium on Amyloidosis
9/14/2020
Company presents robust data, including eight posters, at virtual ISA2020 in partnership with University of Tennessee Demonstrates scientific progress in the diagnosis and treatment of systemic amyloidosis through novel pan-amyloid targeting agents AT-01 and AT-02